Breast Cancer
Conditions
Brief summary
Contrast-enhanced breast CT is a novel high resolution and fully 3D imaging method to document abnormalities within the breast. I will establish its value for breast cancer staging and in monitoring therapy response.
Detailed description
Breast CT is a novel modality that has not been largely evaluated in a clinical setting. Only recently FDA and CE marked BCT machines have been released, and the number of installed bases internationally is below 10 (although rapidly rising). Internationally only a few studies on contrast enhanced breast CT have been performed in small numbers of patients, albeit with excellent results. Nevertheless, substantial evidence for this novel modality is still absent. In particular, the correlation of enhancement and histological grade of DCIS, correlation of CEBCT findings with histopathology, and prediction and assessment of primary systemic treatment are open fields for which more substantial evaluation is clearly needed. In this study we want to establish the value of CEBCT in staging of women with breast cancer, particularly those with extensive carcinoma in situ (DCIS), and in the evaluation of women treated with primary systemic therapy.
Interventions
DEVICEDedicated breast CT
Administration of contrast agent and scanning of the breast in order to evaluate the enhancement of the tumor
Sponsors
The Netherlands Cancer Institute
Radboud University Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnoses of breast cancer * Scheduled for a pre-surgery staging contrast enhanced breast MRI * Eligible for primary systemic therapy
Exclusion criteria
* Women with suspected or confirmed pregnancy * Women with prior history of breast cancer * Women who are breastfeeding * Women who are very frail and unable to cooperate * Women who cannot give informed consent * Contra indication of iodine contrast (i.e. untreatable contrast allergy, renal function impairment (GFR \<60 ml/min/1.73m2)) * Contra indication for irradiation (i.e. genetic mutation that predispose to breast cancer) * Male subjects
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Non-inferiority of CEBCT error rate vs DCE MRI error rate, both as compared to the golden standard for tumor staging. | 3 years | Non-inferiority of CEBCT error rate against the golden standard, i.e. histopathology, to DCE MRI error rate against the golden standard for tumor staging. i.e. histopathology, to DCE MRI error rate against the golden standard for tumor staging. |
| Non-inferiority of CEBCT to predict pCR after primary systemic therapy as compared to DCE MRI. | 3 years | Non-inferiority of CEBCT to predict pCR after primary systemic therapy as compared to DCE MRI computed from the area under the receiver operating characteristic (ROC) curve (AUC) (or AUROC). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Concordance of tumor extent between CEBCT and large section histopathology | 3 years | We will evaluate the rate of concordance between the size of the tumour determined at CEBCT images and those at final histopathology sections |
| Frequency of detection of contralateral cancers with CEBCT | 3 years | We will record how many times we will find a contralateral incidental breast cancer, not previously reported, after performing CEBCT |
| Concordance between morphological and enhancement characteristics of cancers on CEBCT to their expected response to primary systemic therapy. | 3 years | We will evaluate the rate of concordance of breast cancer response to primary systemic therapy compared to the expected response based on literature by evaluating their morphological and enhancement characteristics at CEBCT examinations |
| Potential of CEBCT predicting the response to primary systemic therapy early in treatment | 3 years | We will assess the potential of CEBCT in predicting the response of breast cancer to primary systemic therapy as compared to the assessment made at final histopathology section |
Contacts
Primary ContactAlma Hoxhaj, MD
Outcome results
None listed